Agile Therapeutics Inc
F:0AL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tiong Nam Logistics Holdings Bhd
KLSE:TNLOGIS
|
MY |
|
T
|
Tansun Technology Co Ltd
SZSE:300872
|
CN |
Agile Therapeutics Inc
Net Income
Agile Therapeutics Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Agile Therapeutics Inc
F:0AL
|
Net Income
-$7.8m
|
CAGR 3-Years
50%
|
CAGR 5-Years
15%
|
CAGR 10-Years
1%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$26.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Agile Therapeutics Inc
Glance View
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. The company is headquartered in Princeton, New Jersey and currently employs 30 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.
See Also
What is Agile Therapeutics Inc's Net Income?
Net Income
-7.8m
USD
Based on the financial report for Mar 31, 2024, Agile Therapeutics Inc's Net Income amounts to -7.8m USD.
What is Agile Therapeutics Inc's Net Income growth rate?
Net Income CAGR 10Y
1%
Over the last year, the Net Income growth was 59%. The average annual Net Income growth rates for Agile Therapeutics Inc have been 50% over the past three years , 15% over the past five years , and 1% over the past ten years .
